A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:1. doi:10.3322/caac.21442
   Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg. 2001;233(2):236–241. doi:10.1097/00000658-200102000-00013
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21(28):8478–8491. doi:10.3748/wjg.v21.i28.8478
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang M, Zhu J, et al. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biom Pharmacother. 2020;132:110797. doi:10.1016/j.biopha.2020.110797
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Yamada K, Yamamoto N, Yamada Y, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011;17(8):2528–2537. doi:10.1158/1078-0432.CCR-10-2638
   PubMed Web of Science ®Google Scholar
• Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106(10):1598–1604. doi:10.1038/bjc.2012.154
   PubMed Web of Science ®Google Scholar
• Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007;7(7):543–555. doi:10.1038/nri2103
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400. doi:10.1038/nrd1381
   PubMed Web of Science ®Google Scholar
• Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 Antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers. 2020;12:5. doi:10.3390/cancers12051089
   Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Kudo M, Ikeda M, Motomura K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): study 117. J Clin Oncol. 2020;38(4_suppl):513. doi:10.1200/JCO.2020.38.4_suppl.513
   Web of Science ®Google Scholar
• Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 2019;11(8):1443–1451. doi:10.1080/19420862.2019.1654303
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. NCCN Guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw. 2017;15(5):563–573. doi:10.6004/jnccn.2017.0059
   PubMed Web of Science ®Google Scholar
• Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49(5):523–529. doi:10.1080/02841850801958890
   PubMed Web of Science ®Google Scholar
• Fu Z, Li X, Zhong J, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15:663–675. doi:10.1007/s12072-021-10184-9
   PubMed Web of Science ®Google Scholar
• Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study. Cancer. 2021;127:3782–3793. doi:10.1002/cncr.33677
   PubMed Web of Science ®Google Scholar
• Mai Q, Mo Z, Shi F, Chen X. Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2020;38(15_suppl):e16603–e16603. doi:10.1200/JCO.2020.38.15_suppl.e16603
   Web of Science ®Google Scholar
• He M-K, Liang R-B, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:175883592110027. doi:10.1177/17588359211002720
   Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi:10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306. doi:10.1016/j.jhep.2019.09.026
   PubMed Web of Science ®Google Scholar
• Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669–3676. doi:10.1007/s00520-016-3297-9
   PubMed Web of Science ®Google Scholar
• Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227–252. doi:10.21037/hbsn-21-328
   PubMed Web of Science ®Google Scholar
• Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387. doi:10.3389/fimmu.2022.848387
   PubMed Web of Science ®Google Scholar
• Sun HC, Zhu XD. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview. Front Oncol. 2021;11:772195. doi:10.3389/fonc.2021.772195
   PubMed Web of Science ®Google Scholar
• Tang H, Cao Y, Jian Y, et al. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: a review. Biosci Trends. 2022;16(2):130–141. doi:10.5582/bst.2022.01019
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Shafer AD, Selinkoff PM. Preoperative irradiation and chemotherapy for initially unresectable hepatoblastoma. J Pediatr Surg. 1977;12(6):1001–1007. doi:10.1016/0022-3468(77)90612-1
   PubMed Web of Science ®Google Scholar
• Zhu X-D, Huang C, Shen Y-H, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and Anti-PD-1 antibody combinations. Liver Cancer. 2021;2021:1–10.
   Google Scholar
• Zhang Y, Huang G, Wang Y, et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? Ten years of experience. Oncologist. 2016;21(12):1442–1449. doi:10.1634/theoncologist.2016-0094
   PubMed Web of Science ®Google Scholar
• He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960. doi:10.1001/jamaoncol.2019.0250
   PubMed Web of Science ®Google Scholar
• Tomonari T, Sato Y, Tanaka H, et al. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: three case reports. Medicine. 2020;99(42):e22782. doi:10.1097/MD.0000000000022782
   PubMed Web of Science ®Google Scholar
• Raoul J-L, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002
   PubMed Web of Science ®Google Scholar
• Hata K, Suetsugu K, Egashira N, et al. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol. 2020;86(6):803–813. doi:10.1007/s00280-020-04178-x
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Lau WY, Lai ECH. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. Ann Surg Oncol. 2007;14(12):3301–3309. doi:10.1245/s10434-007-9549-7
   PubMed Web of Science ®Google Scholar
• Colombo PE, Quenet F, Alric P, et al. Distal pancreatectomy with celiac axis resection (Modified Appleby Procedure) and arterial reconstruction for locally advanced pancreatic adenocarcinoma after FOLFIRINOX chemotherapy and chemoradiation therapy. Ann Surg Oncol. 2021;28(2):1106–1108. doi:10.1245/s10434-020-08740-y
   PubMed Web of Science ®Google Scholar
• Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–1661.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li K, et al. Overall survival (OS) update in ALTER 1202: anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Ann Oncol. 2019;30:v711.
   Google Scholar
• Li L, Li B, Zhang M. Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis. Acta Radiol. 2020;61(6):723–731. doi:10.1177/0284185119878357
   PubMed Web of Science ®Google Scholar
• Zhang X-P, Chai Z-T, Gao Y-Z, et al. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB. 2019;21(12):1687–1696. doi:10.1016/j.hpb.2019.04.014
   PubMed Web of Science ®Google Scholar
• Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15:155–160. doi:10.5582/bst.2021.01091
   PubMed Web of Science ®Google Scholar
• Song T, Lang M, Ren S, Gan L, Lu W. The past, present and future of conversion therapy for liver cancer. Am J Cancer Res. 2021;11(10):4711–4724.
   PubMed Web of Science ®Google Scholar